WIRB: BI 1200.209 A Single Arm Phase IV Study of Afatinib in Elderly Patients with recurrent or Stage IV Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have Common Epidermal Growth Factor Receptor (EGFR) mutations (Exon 19 Deletions or Exon 21 L858R Substitution Mutations)
Cancer - Lung
John McCann, MD
Damour Center for Cancer Care
3350 Main Street
Springfield, MA 01199
While there are some treatment options available for the specific type of lung cancer you have, there is a need to improve the tolerability of treatment in an older population. Afatinib is approved in the US to treat your type of lung cancer. The purpose of this study is to see what side effects lead to dose reduction of afatinib in participants who are 70 years old or older.
70 years or older, with recurrent or Stage IV Non-Small Cell Lung Cancer (NSCLC)